Orlando, FL -- (SBWIRE) -- 06/19/2015 -- Psoriatic arthritis is an inflammatory arthritis that affects about 30 percent of individuals with the skin condition, which is characterized by scaly, red and painful rashes. The condition can lead to inflammation, pain and joint damage. Fortunately, there seems to be good news for patients.
Research suggests that a treat-to-target strategy can potentially work well for psoriatic arthritis patients. This aggressive treatment is known to address several symptoms of the disease and also provides better outcomes.
In a study presented at the American College of Rheumatology, it was revealed that an aggressive and strict protocol known as "treat to target" is used to treat patients to help them gain better control of their disease than individuals who received just the standard care.
"It has been shown in the previous studies that the treat-to-target method has resulted in better outcomes in individuals who suffered from rheumatoid arthritis and other types of inflammatory arthritis," said VitaBreeze Supplements spokesperson, Michelle O'Sullivan.
Laura C. Coates, M.D., University of Leeds' lecturer and study author, noted that the study was the first to assess a treatment-to-target strategy among psoriatic arthritis patients. Treating to a specific target has led to the improvement in clinical outcomes for individuals suffering from psoriatic arthritis.
The study involved 206 patients who suffered from PsA symptoms for less than 2 years and did not take DMARDs, or disease-modifying antirheumatic drugs, such as leflunomide. The group was randomized to have standard therapy or "treat to target" (T2T). The group who received methotrexate were asked about their ability to perform daily tasks, pain and disease activity. They were also evaluated for tender spots and swollen joints, or whether the skin psoriasis was active.
Patients who did not achieve disease activity after 12 weeks were given additional DMARDs. Those who did not reach the target of minimal disease activity were made to administer a biologic drug or use another DMARD with methotrexate. On the other hand, those who belong to the standard care group were given DMARDs, but were also not treated based on any escalation plan, target or schedule. The treatment was also made according to what the doctor preferred.
Arthritis sufferers often deal with the symptoms caused by their condition through exhausting all the potentially effective treatments available on the market. In addition to pain relief drugs, there are also patients who use natural alternatives such as curcumin supplements. Curcumin is believed to be a powerful anti-inflammatory ingredient that is widely used by arthritis patients (http://amazon.com/Turmeric-Curcumin-Complex-BioPerine-Bio-availability/dp/B00JA4TLTI/).
VitaBreeze is a nutraceutical brand that manufactures high-quality natural supplements to help people live a healthy, enjoyable and longer life. All of the company's products are manufactured in the United States using the finest quality ingredients that have been carefully selected, tested and crafted into the firm's winning formulas.
Visit http://www.VitaBreeze.com to learn more.
MEDIA CONTACT INFORMATION: